Skip to Content

September 15, 2020

Following recommendations issued by Governor Cooper and the CDC, the NC Chamber’s Health Care Conference will be a virtual event. Our team remains in close contact with state officials and we feel that this decision is in the best interest of the health and welfare of our community. Thank you for understanding. 

COVID-19 has indelibly changed the way we deliver health care in North Carolina and across the world. As we wait for a vaccine, providers, suppliers and insurers must all navigate a tempest of uncertainty while continuing to deliver high value care to patients across the state. This year’s Health Care Conference will examine our evolving health care landscape and provide testing and treatment updates from vaccine manufacturers, perspectives from hospital leaders, and voices from the overall health care supply chain. Guests will leave with a much more holistic view of COVID-19’s impact on the people and health care infrastructure of North Carolina, as well the future of care throughout our state.

Learn how the NC Chamber is advocating for improved health care value here. 

Presented By
  • Pfizer Logo


Tuesday, September 15
7:50 amAttendees Admitted to Conference
8:00 amWelcome and Introductory Remarks
8:10 amOpening Keynote

Dr. Tunde Sotunde, CEO, Blue Cross NC

8:40 amNetworking Break
8:55 amCOVID19: Testing, Treatment and Vaccine Development
  • Dr. Len Friedland, Vice President and Director for Scientific Affairs and Public Health, GSK
  • Dr. Oren Cohen, Chief Medical Officer, Covance
  • Dr. David Wohl, Professor of Medicine, Division of Infectious Diseases, UNC School of Medicine
  • Moderator:  Shaylah Nunn Jones, Principal, Government & Public Affairs, Novo Nordisk Pharmaceutical Industries, LP
9:40 amReducing Healthcare Costs and Improving Patient Care through Biosimilars

Robert Popovian, PharmD, Vice President, US Government Relations, Pfizer

Employers have a new instrument in their drug-management toolkit: biosimilars. Mirroring the use of generic drugs for brand-name non-biologic drugs, biosimilars have the promise of being less expensive alternatives to their biologic brand-name counterparts. Hence, it is important for employers to adopt utilization of biosimilars in their benefit plans.


9:50 amNetworking Break
10:05 amA Conversation with Hospital Leadership
10:50 amNetworking Break
11:05 amHealth Care Supply Chain: Challenges and Improvements
  • Michael J. Akire, President, Premier
  • Jerry Cook, Vice President, Government and Trade Relations, Hanesbrands, Inc.
  • John Loyack, Vice President, Global Business Services, Economic Development Partnership of North Carolina
  • Moderator:  Kelly Fuller, President, NC Chamber Foundation
11:50 amClosing Remarks